There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CalciMedica (CALC – Research Report) and Y-Mabs Therapeutics (YMAB – Research Report) with bullish sentiments.
CalciMedica (CALC)
JonesTrading analyst Catherine Novack maintained a Buy rating on CalciMedica on July 9 and set a price target of $15.00. The company’s shares closed last Thursday at $4.72.
According to TipRanks.com, Novack is ranked 0 out of 5 stars with an average return of -9.7% and a 35.5% success rate. Novack covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Daré Bioscience, and Purple Biotech.
CalciMedica has an analyst consensus of Strong Buy, with a price target consensus of $18.33, representing a 295.0% upside. In a report issued on June 28, Oppenheimer also maintained a Buy rating on the stock with a $14.00 price target.
See the top stocks recommended by analysts >>
Y-Mabs Therapeutics (YMAB)
The company’s shares closed last Thursday at $12.07.
According to TipRanks.com, Walsh is a 1-star analyst with an average return of -2.6% and a 36.2% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Perspective Therapeutics, and TriSalus Life Sciences.
Currently, the analyst consensus on Y-Mabs Therapeutics is a Strong Buy with an average price target of $31.20, representing a 162.6% upside. In a report issued on June 28, Truist Financial also initiated coverage with a Buy rating on the stock with a $21.00 price target.
Read More on CALC: